4.7 Article

Distinct contributions of partial and full EMT to breast cancer malignancy

期刊

DEVELOPMENTAL CELL
卷 56, 期 23, 页码 3203-+

出版社

CELL PRESS
DOI: 10.1016/j.devcel.2021.11.006

关键词

-

资金

  1. SystemsX.ch MTD project MetastasiX
  2. Swiss National Science Foundation
  3. Swiss Cancer League
  4. Krebsliga Beider Basel
  5. MD-PhD fellowship of the Swiss National Science Foundation
  6. Swiss Cancer Research Foundation [323630-139118]
  7. European Research Council (ERC) CoG Cancer-recurrence [648804]
  8. Cancer Genomics Netherlands
  9. Doctor Josef Steiner Foundation

向作者/读者索取更多资源

EMT is a transient and reversible process where cancer cells transition between epithelial and mesenchymal states. Partial EMT cells contribute to metastasis and chemoresistance, while full EMT cells fail to colonize the lungs but are enriched in recurrent tumors post-chemotherapy.
Epithelial-mesenchymal transition (EMT) is a transient, reversible process of cell de-differentiation where cancer cells transit between various stages of an EMT continuum, including epithelial, partial EMT, and mesenchymal cell states. We have employed Tamoxifen-inducible dual recombinase lineage tracing systems combined with live imaging and 5-cell RNA sequencing to track cancer cells undergoing partial or full EMT in the MMTV-PyMT mouse model of metastatic breast cancer. In primary tumors, cancer cells infrequently undergo EMT and mostly transition between epithelial and partial EMT states but rarely reach full EMT. Cells undergoing partial EMT contribute to lung metastasis and chemoresistance, whereas full EMT cells mostly retain a mesenchymal phenotype and fail to colonize the lungs. However, full EMT cancer cells are enriched in recurrent tumors upon chemotherapy. Hence, cancer cells in various stages of the EMT continuum differentially contribute to hallmarks of breast cancer malignancy, such as tumor invasion, metastasis, and chemoresistance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据